Q2 EPS Estimate for Eledon Pharmaceuticals Lifted by Analyst

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Eledon Pharmaceuticals in a report issued on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.26) per share for the quarter, up from their prior estimate of ($0.29). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals' Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($1.19) EPS and FY2029 earnings at ($0.50) EPS.

Separately, Guggenheim began coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a "buy" rating and a $9.00 price target on the stock.

Eledon Pharmaceuticals Trading Down 0.7%

Shares of ELDN opened at $2.87 on Monday. Eledon Pharmaceuticals has a twelve month low of $2.30 and a twelve month high of $5.54. The stock's 50 day moving average is $3.17 and its two-hundred day moving average is $3.94. The firm has a market capitalization of $171.86 million, a PE ratio of -1.43 and a beta of 0.08.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.20.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. RA Capital Management L.P. purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $14,693,000. Sphera Funds Management LTD. boosted its stake in shares of Eledon Pharmaceuticals by 96.7% during the 4th quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock worth $10,513,000 after acquiring an additional 1,254,298 shares in the last quarter. First Light Asset Management LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $9,595,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $8,075,000. Finally, Woodline Partners LP boosted its stake in shares of Eledon Pharmaceuticals by 98.3% during the 4th quarter. Woodline Partners LP now owns 1,671,822 shares of the company's stock worth $6,888,000 after acquiring an additional 828,930 shares in the last quarter. Hedge funds and other institutional investors own 56.77% of the company's stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.